SRR12202421
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.380
- G2M_CHECKPOINT+0.340
- OXIDATIVE_PHOSPHORYLATION+0.310
- BILE_ACID_METABOLISM+0.280
- MTORC1_SIGNALING+0.250
- PEROXISOME+0.250
- UNFOLDED_PROTEIN_RESPONSE+0.250
- PROTEIN_SECRETION+0.230
- ADIPOGENESIS+0.210
- MYC_TARGETS_V1+0.190
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.450
- INFLAMMATORY_RESPONSE-0.360
- TGF_BETA_SIGNALING-0.360
- IL6_JAK_STAT3_SIGNALING-0.350
- WNT_BETA_CATENIN_SIGNALING-0.350
- COAGULATION-0.330
- APICAL_SURFACE-0.310
- APICAL_JUNCTION-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- NOTCH_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.921 |
| 2 | SRR26320065 | — | — | 0.918 |
| 3 | DRR168601 | — | — | 0.916 |
| 4 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.899 |
| 5 | R150 | — | — | 0.898 |
| 6 | 5ab068b1-411a-4083-a1ab-3ca7569a54a0 | — | — | 0.894 |
| 7 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.893 |
| 8 | SRR26320088 | — | — | 0.892 |
| 9 | R239 | — | — | 0.886 |
| 10 | 2d8cab40-0dda-4d6d-a9ba-83a82a7e1c15 | — | — | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |